FDA Approval Delays Mount After Staff Layoffs
FDA staff are struggling to meet product review deadlines, a situation exacerbated by recent significant layoffs. The sheer number of employees let go is staggering, adding to already existing staffing shortages and creating a perfect storm of delayed approvals. This isn’t just impacting review times; it represents a systematic weakening of regulatory oversight.
The reduced workforce directly translates into a longer wait for product approvals. This backlog means medical devices and pharmaceuticals are taking significantly longer to reach the market, potentially delaying access to vital treatments for patients. The impact extends beyond simply slowing down the process; it introduces a significant risk to public health.… Continue reading
Matt Underwood